Scarica l'app Stockscreener
1.56
70.59%
0.6455
Dopo l'orario di chiusura:
1.46
-0.10
-6.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Needham cuts Neumora stock price target on navacaprant discontinuation By Investing.com - Investing.com Canada
Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy - Investing.com Canada
Neumora bins depression drug after Phase III failures - The Pharma Letter
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Asianet Newsable
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Benzinga
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc. - GlobeNewswire
Neumora plummets as phase 3 navacaprant data misses key goal - MSN
Neumora shifts focus to Alzheimer's and obesity drugs after navacaprant setback - The Business Journals
Neumora scraps depression drug development after repeated trial failures - Reuters
Neumora discards depression asset, lays off staffers after pair of late-stage flops - BioSpace
Neumora Therapeutics Discontinues Navacaprant After Phase 3 Failure, Advances Alzheimer’s and Schizophrenia Pipeline - Minichart
Neumora stock plunges after phase 3 trial failure By Investing.com - Investing.com South Africa
Navacaprant fails Phase 3 trials; Neumora halts its development, focusing on other drug candidates. - Pluang
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) - Yahoo Finance
Neumora pulls plug off depression drug after trial failures, cut jobs - Investing.com Canada
Neumora Ends Navacaprant After Phase 3 Trial Failure - TipRanks
Neumora discontinues navacaprant after phase 3 trial failures - Investing.com
Neumora discontinues navacaprant after phase 3 trial failures By Investing.com - Investing.com Canada
Neumora Therapeutics scraps depression drug after two late-stage trial failures - TradingView
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update - The Manila Times
Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline - Stock Titan
CRNX,NMRA Volatility & Greeks - Finviz
Neumora Therapeutics (NMRA) Slips Near Key Support; Oversold Conditions LoomMonthly Profile - newsline.com
Neumora Therapeutics advances pipeline for brain penetrant therapies in neurodegenerative and neuropsychiatric disease - Traders Union
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics commits to accelerating Alzheimer agitation therapies - Traders Union
Neumora Shareholders Approve Directors, Auditor and Executive Pay - The Globe and Mail
Neumora (NMRA) director and 10% owner receives 80,000 stock options at $1.86 - Stock Titan
NMRANeumora Therapeutics Inc. stock news, filings & ratings - Quantisnow
Neumora Therapeutics (NMRA) director granted 80,000 options at $1.86 - Stock Titan
Neumora Therapeutics (NMRA) director granted 80,000 stock options at $1.86 - Stock Titan
Neumora (NASDAQ: NMRA) director receives 80,000 stock options grant - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) investors approve directors, auditor and annual pay vote - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts - TipRanks
Number of shareholders of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Neumora Therapeutics (NMRA) Edges Lower as Stock Tests Key Support at $1.75Debt Free Companies - newsline.com
Neumora Therapeutics (NMRA) Slides 2.16% as Stock Tests Key Support LevelsRetail Driven Moves - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 Amid Mixed SentimentWyckoff Upthrust - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Consolidation ContinuesDividend Arbitrage - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue PhaseEBITDA Margin Trends - The Legal Advocate
Neumora Therapeutics (NMRA): Stock Holds Steady at $1.85 as Key Support and Resistance Levels TightenIV Crush Alert - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Disciplined SpendingEarnings Revision Report - newsline.com
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Stock Navigates Tight RangeTrader Community Signals - Newser
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Operational DisciplineLow Growth Earnings - Newser
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst - TipRanks
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
K2HV Equity reports 5.79M conversion shares for Neumora (NMRA) - Stock Titan
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target - TipRanks
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):